- Home
- NUVB vs APLS Comparison
NUVB vs APLS Comparison
Compare NUVB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVB | APLS |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NUVB | APLS |
|---|---|---|
| Price | $8.98 | $25.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | $10.63 | ★ $33.89 |
| AVG Volume (30 Days) | ★ 6.1M | 2.3M |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | $26,748,000.00 | ★ $1,016,397,000.00 |
| Revenue This Year | $609.55 | $28.88 |
| Revenue Next Year | $197.91 | N/A |
| P/E Ratio | ★ N/A | $70.48 |
| Revenue Growth | ★ 1137.19 | 42.11 |
| 52 Week Low | $1.54 | $16.10 |
| 52 Week High | $9.75 | $35.57 |
Technical Indicators
Market Signals| Indicator | NUVB | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 59.78 |
| Support Level | $8.84 | $24.56 |
| Resistance Level | $9.75 | $25.77 |
| Average True Range (ATR) | 0.43 | 1.00 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 56.50 | 52.25 |
Price Performance
Historical ComparisonAbout NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.